

Irene Oi-lin Ng

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1212352/publications.pdf>

Version: 2024-02-01

244
papers

20,958
citations

8159

76
h-index

11581

135
g-index

246
all docs

246
docs citations

246
times ranked

24908
citing authors

#	ARTICLE	IF	CITATIONS
1	Identification and Characterization of Tumorigenic Liver Cancer Stem/Progenitor Cells. <i>Gastroenterology</i> , 2007, 132, 2542-2556.	0.6	1,096
2	RNA N6-methyladenosine methyltransferase-like 3 promotes liver cancer progression through YTHDF2-dependent posttranscriptional silencing of SOCS2. <i>Hepatology</i> , 2018, 67, 2254-2270.	3.6	980
3	MicroRNA Expression, Survival, and Response to Interferon in Liver Cancer. <i>New England Journal of Medicine</i> , 2009, 361, 1437-1447.	13.9	778
4	Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. <i>Cancer</i> , 2000, 89, 500-507.	2.0	678
5	Tumor size predicts vascular invasion and histologic grade: Implications for selection of surgical treatment for hepatocellular carcinoma. <i>Liver Transplantation</i> , 2005, 11, 1086-1092.	1.3	555
6	CD24+ Liver Tumor-Initiating Cells Drive Self-Renewal and Tumor Initiation through STAT3-Mediated NANOG Regulation. <i>Cell Stem Cell</i> , 2011, 9, 50-63.	5.2	545
7	Improving Survival Results After Resection of Hepatocellular Carcinoma: A Prospective Study of 377 Patients Over 10 Years. <i>Annals of Surgery</i> , 2001, 234, 63-70.	2.1	517
8	Genome-Wide Association Study in Asian Populations Identifies Variants in ETS1 and WDFY4 Associated with Systemic Lupus Erythematosus. <i>PLoS Genetics</i> , 2010, 6, e1000841.	1.5	378
9	Hypoxia-inducible factor 1 is a master regulator of breast cancer metastatic niche formation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 16369-16374.	3.3	375
10	Non-coding RNAs in hepatocellular carcinoma: molecular functions and pathological implications. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2018, 15, 137-151.	8.2	325
11	Hypoxia inducible factor HIF-1 promotes myeloid-derived suppressor cells accumulation through ENTPD2/CD39L1 in hepatocellular carcinoma. <i>Nature Communications</i> , 2017, 8, 517.	5.8	319
12	The MicroRNA miR-139 Suppresses Metastasis and Progression of Hepatocellular Carcinoma by Down-regulating Rho-Kinase 2. <i>Gastroenterology</i> , 2011, 140, 322-331.	0.6	268
13	Tumor Microvessel Density as a Predictor of Recurrence After Resection of Hepatocellular Carcinoma: A Prospective Study. <i>Journal of Clinical Oncology</i> , 2002, 20, 1775-1785.	0.8	263
14	Enhancer of zeste homolog 2 epigenetically silences multiple tumor suppressor microRNAs to promote liver cancer metastasis. <i>Hepatology</i> , 2012, 56, 622-631.	3.6	255
15	Cancer-Associated Fibroblasts Regulate Tumor-Initiating Cell Plasticity in Hepatocellular Carcinoma through c-Met/FRA1/HEY1 Signaling. <i>Cell Reports</i> , 2016, 15, 1175-1189.	2.9	253
16	Genome-wide CRISPR/Cas9 library screening identified PHGDH as a critical driver for Sorafenib resistance in HCC. <i>Nature Communications</i> , 2019, 10, 4681.	5.8	229
17	Multidimensional analyses reveal distinct immune microenvironment in hepatitis B virus-related hepatocellular carcinoma. <i>Gut</i> , 2019, 68, 916-927.	6.1	228
18	MicroRNA-125b suppressed human liver cancer cell proliferation and metastasis by directly targeting oncogene LIN28B2. <i>Hepatology</i> , 2010, 52, 1731-1740.	3.6	225

#	ARTICLE	IF	CITATIONS
19	HBsAg seroclearance in chronic hepatitis B in the Chinese: Virological, histological, and clinical aspects. <i>Hepatology</i> , 2004, 39, 1694-1701.	3.6	222
20	Serum Vascular Endothelial Growth Factor Predicts Venous Invasion in Hepatocellular Carcinoma : A Prospective Study. <i>Annals of Surgery</i> , 2001, 233, 227-235.	2.1	217
21	Hepatectomy for hepatocellular carcinoma with major portal or hepatic vein invasion: Results of a multicenter study. <i>Surgery</i> , 2005, 137, 403-410.	1.0	215
22	Abdominal Drainage After Hepatic Resection Is Contraindicated in Patients With Chronic Liver Diseases. <i>Annals of Surgery</i> , 2004, 239, 194-201.	2.1	208
23	Critical Appraisal of the Clinical and Pathologic Predictors of Survival After Resection of Large Hepatocellular Carcinoma. <i>Archives of Surgery</i> , 2005, 140, 450.	2.3	203
24	Lysyl oxidase-like 2 is critical to tumor microenvironment and metastatic niche formation in hepatocellular carcinoma. <i>Hepatology</i> , 2014, 60, 1645-1658.	3.6	197
25	AMPK Promotes p53 Acetylation via Phosphorylation and Inactivation of SIRT1 in Liver Cancer Cells. <i>Cancer Research</i> , 2012, 72, 4394-4404.	0.4	189
26	Transketolase counteracts oxidative stress to drive cancer development. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E725-34.	3.3	186
27	Meta-analysis Followed by Replication Identifies Loci in or near CDKN1B, TET3, CD80, DRAM1, and ARID5B as Associated with Systemic Lupus Erythematosus in Asians. <i>American Journal of Human Genetics</i> , 2013, 92, 41-51.	2.6	184
28	Hypoxia induces myeloid-derived suppressor cell recruitment to hepatocellular carcinoma through chemokine (CCL20 motif) ligand 26. <i>Hepatology</i> , 2016, 64, 797-813.	3.6	170
29	Deleted in Liver Cancer (DLC) 2 Encodes a RhoGAP Protein with Growth Suppressor Function and Is Underexpressed in Hepatocellular Carcinoma. <i>Journal of Biological Chemistry</i> , 2003, 278, 10824-10830.	1.6	167
30	Blockade of CD47-mediated cathepsin S/protease-activated receptor 2 signaling provides a therapeutic target for hepatocellular carcinoma. <i>Hepatology</i> , 2014, 60, 179-191.	3.6	167
31	Genetic and epigenetic alterations of DLC-1 gene in hepatocellular carcinoma. <i>Cancer Research</i> , 2003, 63, 7646-51.	0.4	164
32	Rho GTPase-Activating Protein Deleted in Liver Cancer Suppresses Cell Proliferation and Invasion in Hepatocellular Carcinoma. <i>Cancer Research</i> , 2005, 65, 8861-8868.	0.4	160
33	Long-term results of resection for large hepatocellular carcinoma: A multivariate analysis of clinicopathological features. <i>Hepatology</i> , 1990, 11, 815-818.	3.6	152
34	Microvessel Density, Vascular Endothelial Growth Factor and Its Receptors Flt-1 and Flk-1/KDR in Hepatocellular Carcinoma. <i>American Journal of Clinical Pathology</i> , 2001, 116, 838-845.	0.4	151
35	Nuclear factor kappa B-mediated CD47 upregulation promotes sorafenib resistance and its blockade synergizes the effect of sorafenib in hepatocellular carcinoma in mice. <i>Hepatology</i> , 2015, 62, 534-545.	3.6	149
36	Clinicopathologic Features of Long-Term Survivors and Disease-Free Survivors After Resection of Hepatocellular Carcinoma: A Study of a Prospective Cohort. <i>Journal of Clinical Oncology</i> , 2001, 19, 3037-3044.	0.8	148

#	ARTICLE	IF	CITATIONS
37	SENP1 promotes hypoxia-induced cancer stemness by HIF-1 α deSUMOylation and SENP1/HIF-1 α positive feedback loop. <i>Gut</i> , 2017, 66, 2149-2159.	6.1	141
38	Up-regulation of histone methyltransferase SETDB1 by multiple mechanisms in hepatocellular carcinoma promotes cancer metastasis. <i>Hepatology</i> , 2016, 63, 474-487.	3.6	140
39	Deregulation of microRNA expression occurs early and accumulates in early stages of HBV-associated multistep hepatocarcinogenesis. <i>Journal of Hepatology</i> , 2011, 54, 1177-1184.	1.8	136
40	Single-cell RNA sequencing shows the immunosuppressive landscape and tumor heterogeneity of HBV-associated hepatocellular carcinoma. <i>Nature Communications</i> , 2021, 12, 3684.	5.8	136
41	Determination of the molecular relationship between multiple tumour nodules in hepatocellular carcinoma differentiates multicentric origin from intrahepatic metastasis. <i>Journal of Pathology</i> , 2003, 199, 345-353.	2.1	131
42	Macrophage migration inhibitory factor: Roles in regulating tumor cell migration and expression of angiogenic factors in hepatocellular carcinoma. <i>International Journal of Cancer</i> , 2003, 107, 22-29.	2.3	129
43	Single-cell transcriptomics reveals the landscape of intra-tumoral heterogeneity and stemness-related subpopulations in liver cancer. <i>Cancer Letters</i> , 2019, 459, 176-185.	3.2	129
44	Clinicopathological and prognostic significance of serum and tissue Dickkopf-1 levels in human hepatocellular carcinoma. <i>Liver International</i> , 2011, 31, 1494-1504.	1.9	127
45	Long non-coding RNA HOTTIP is frequently up-regulated in hepatocellular carcinoma and is targeted by tumour suppressive miR-125b. <i>Liver International</i> , 2015, 35, 1597-1606.	1.9	126
46	Correlation of serum basic fibroblast growth factor levels with clinicopathologic features and postoperative recurrence in hepatocellular carcinoma. <i>American Journal of Surgery</i> , 2001, 182, 298-304.	0.9	125
47	Stearoyl-CoA desaturase regulates sorafenib resistance via modulation of ER stress-induced differentiation. <i>Journal of Hepatology</i> , 2017, 67, 979-990.	1.8	124
48	C-terminal truncated hepatitis B virus x protein is associated with metastasis and enhances invasiveness by c-jun/matrix metalloproteinase protein 10 activation in hepatocellular carcinoma. <i>Hepatology</i> , 2013, 57, 131-139.	3.6	123
49	Liver Transplantation in Asian Patients With Chronic Hepatitis B Using Lamivudine Prophylaxis. <i>Annals of Surgery</i> , 2001, 233, 276-281.	2.1	122
50	Doxorubicin-induced apoptosis and chemosensitivity in hepatoma cell lines. <i>Cancer Chemotherapy and Pharmacology</i> , 2002, 49, 78-86.	1.1	122
51	Rho-kinase 2 is frequently overexpressed in hepatocellular carcinoma and involved in tumor invasion. <i>Hepatology</i> , 2009, 49, 1583-1594.	3.6	122
52	P21-Activated Protein Kinase Is Overexpressed in Hepatocellular Carcinoma and Enhances Cancer Metastasis Involving c-Jun NH2-Terminal Kinase Activation and Paxillin Phosphorylation. <i>Cancer Research</i> , 2007, 67, 3601-3608.	0.4	118
53	Histone methyltransferase G9a promotes liver cancer development by epigenetic silencing of tumor suppressor gene RARRES3. <i>Journal of Hepatology</i> , 2017, 67, 758-769.	1.8	118
54	Prickle-1 Negatively Regulates Wnt/ β -Catenin Pathway by Promoting Dishevelled Ubiquitination/Degradation in Liver Cancer. <i>Gastroenterology</i> , 2006, 131, 1218-1227.	0.6	111

#	ARTICLE	IF	CITATIONS
55	Induction of Oxidative Stress Through Inhibition of Thioredoxin Reductase 1 Is an Effective Therapeutic Approach for Hepatocellular Carcinoma. <i>Hepatology</i> , 2019, 69, 1768-1786.	3.6	111
56	Combined hepatocellular&cholangiocarcinoma: A clinicopathological study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1998, 13, 34-40.	1.4	110
57	Deleted in liver cancer 2 (DLC2) suppresses cell transformation by means of inhibition of RhoA activity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 15207-15212.	3.3	110
58	High frequency of chimerism in transplanted livers. <i>Hepatology</i> , 2003, 38, 989-998.	3.6	107
59	Induction of apoptosis by cisplatin and its effect on cell cycle-related proteins and cell cycle changes in hepatoma cells. <i>Cancer Letters</i> , 2002, 175, 27-38.	3.2	101
60	Folate cycle enzyme MTHFD1L confers metabolic advantages in hepatocellular carcinoma. <i>Journal of Clinical Investigation</i> , 2017, 127, 1856-1872.	3.9	100
61	Hepatocellular Carcinoma Cells Up-regulate PVRL1, Stabilizing PVR and Inhibiting the Cytotoxic T-Cell Response via TIGIT to Mediate Tumor Resistance to PD1 Inhibitors in Mice. <i>Gastroenterology</i> , 2020, 159, 609-623.	0.6	100
62	Interaction of Deleted in Liver Cancer 1 with Tensin2 in Caveolae and Implications in Tumor Suppression. <i>Cancer Research</i> , 2006, 66, 8367-8372.	0.4	99
63	Does the Hepatitis B Antigen HBx Promote the Appearance of Liver Cancer Stem Cells?. <i>Cancer Research</i> , 2011, 71, 3701-3708.	0.4	99
64	Hypoxia regulates the mitochondrial activity of hepatocellular carcinoma cells through HIF/HEY1/PINK1 pathway. <i>Cell Death and Disease</i> , 2019, 10, 934.	2.7	98
65	Down®ulation of TIMP2 by HIF&1&/mi&210/HIF&3& regulatory feedback circuit enhances cancer metastasis in hepatocellular carcinoma. <i>Hepatology</i> , 2016, 64, 473-487.	3.6	96
66	Tissue factor pathway inhibitor-2 as a frequently silenced tumor suppressor gene in hepatocellular carcinoma. <i>Hepatology</i> , 2007, 45, 1129-1138.	3.6	93
67	IRAK1 Augments Cancer Stemness and Drug Resistance via the AP-1/AKR1B10 Signaling Cascade in Hepatocellular Carcinoma. <i>Cancer Research</i> , 2018, 78, 2332-2342.	0.4	93
68	Prognosis After Hepatic Resection for Stage IVA Hepatocellular Carcinoma. <i>Annals of Surgery</i> , 2003, 237, 376-383.	2.1	92
69	Sequential alterations of microrna expression in hepatocellular carcinoma development and venous metastasis. <i>Hepatology</i> , 2012, 55, 1453-1461.	3.6	92
70	Lupeol targets liver tumor-initiating cells through phosphatase and tensin homolog modulation. <i>Hepatology</i> , 2011, 53, 160-170.	3.6	91
71	Histone lysine methyltransferase, suppressor of variegation 3-9 homolog 1, promotes hepatocellular carcinoma progression and is negatively regulated by microRNA-125b. <i>Hepatology</i> , 2013, 57, 637-647.	3.6	90
72	Aberrant Super&Enhancer Landscape in Human Hepatocellular Carcinoma. <i>Hepatology</i> , 2019, 69, 2502-2517.	3.6	90

#	ARTICLE	IF	CITATIONS
73	HDPR1, a novel inhibitor of the WNT/ β 2-catenin signaling, is frequently downregulated in hepatocellular carcinoma: involvement of methylation-mediated gene silencing. <i>Oncogene</i> , 2005, 24, 1607-1614.	2.6	87
74	The liver-enriched transcription factor CREB-H is a growth suppressor protein underexpressed in hepatocellular carcinoma. <i>Nucleic Acids Research</i> , 2005, 33, 1859-1873.	6.5	86
75	Loss of phosphatase and tensin homolog enhances cell invasion and migration through aKT/Sp-1 transcription factor/matrix metalloproteinase 2 activation in hepatocellular carcinoma and has clinicopathologic significance. <i>Hepatology</i> , 2011, 53, 1558-1569.	3.6	82
76	ELF1 is associated with systemic lupus erythematosus in Asian populations. <i>Human Molecular Genetics</i> , 2011, 20, 601-607.	1.4	78
77	Evaluation of Nuclear Factor- κ B, Urokinase-Type Plasminogen Activator, and HBx and Their Clinicopathological Significance in Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2004, 10, 4140-4149.	3.2	77
78	Toll-Like Receptor 3 Expressing Tumor Parenchyma and Infiltrating Natural Killer Cells in Hepatocellular Carcinoma Patients. <i>Journal of the National Cancer Institute</i> , 2012, 104, 1796-1807.	3.0	77
79	Molecular Pathogenesis of Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2016, 5, 290-302.	4.2	77
80	Liver cancer stem cells: implications for a new therapeutic target. <i>Liver International</i> , 2009, 29, 955-965.	1.9	75
81	Caveolin-1 overexpression is associated with hepatocellular carcinoma tumorigenesis and metastasis. <i>Journal of Pathology</i> , 2012, 226, 645-653.	2.1	72
82	Sox9 confers stemness properties in hepatocellular carcinoma through Frizzled-7 mediated Wnt/ β 2-catenin signaling. <i>Oncotarget</i> , 2016, 7, 29371-29386.	0.8	70
83	MiR-200b/200c/429 subfamily negatively regulates Rho/ROCK signaling pathway to suppress hepatocellular carcinoma metastasis. <i>Oncotarget</i> , 2015, 6, 13658-13670.	0.8	70
84	NDUFA4L2 Fine-tunes Oxidative Stress in Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2016, 22, 3105-3117.	3.2	68
85	Overexpression of a Novel Activator of PAK4, the CDK5 Kinase-associated Protein CDK5RAP3, Promotes Hepatocellular Carcinoma Metastasis. <i>Cancer Research</i> , 2011, 71, 2949-2958.	0.4	67
86	Switching of Pyruvate Kinase Isoform L to M2 Promotes Metabolic Reprogramming in Hepatocarcinogenesis. <i>PLoS ONE</i> , 2014, 9, e115036.	1.1	67
87	High-throughput tissue microarray analysis of c-myc activation in chronic liver diseases and hepatocellular carcinoma. <i>Human Pathology</i> , 2004, 35, 1324-1331.	1.1	65
88	Deleted in Liver Cancer 1 (DLC1) Negatively Regulates Rho/ROCK/MLC Pathway in Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2008, 3, e2779.	1.1	62
89	The impact of hypoxia in hepatocellular carcinoma metastasis. <i>Frontiers of Medicine</i> , 2014, 8, 33-41.	1.5	62
90	Anti-CD47 antibody suppresses tumour growth and augments the effect of chemotherapy treatment in hepatocellular carcinoma. <i>Liver International</i> , 2016, 36, 737-745.	1.9	62

#	ARTICLE	IF	CITATIONS
91	Intragraft gene expression profiles by cDNA microarray in small-for-size liver grafts. <i>Liver Transplantation</i> , 2003, 9, 425-432.	1.3	60
92	Upregulation of the Wnt Co-Receptor LRP6 Promotes Hepatocarcinogenesis and Enhances Cell Invasion. <i>PLoS ONE</i> , 2012, 7, e36565.	1.1	60
93	EPHB2 Activates β -Catenin to Enhance Cancer Stem Cell Properties and Drive Sorafenib Resistance in Hepatocellular Carcinoma. <i>Cancer Research</i> , 2021, 81, 3229-3240.	0.4	59
94	Expression of p27KIP1 and p21WAF1/CIP1 in primary hepatocellular carcinoma: Clinicopathologic correlation and survival analysis. <i>Human Pathology</i> , 2001, 32, 778-785.	1.1	58
95	Overriding Adaptive Resistance to Sorafenib Through Combination Therapy With Src Homology 2 Domain-Containing Phosphatase 2 Blockade in Hepatocellular Carcinoma. <i>Hepatology</i> , 2020, 72, 155-168.	3.6	58
96	Cellular heterogeneity and plasticity in liver cancer. <i>Seminars in Cancer Biology</i> , 2022, 82, 134-149.	4.3	58
97	Genome-Wide Association Study of Hepatocellular Carcinoma in Southern Chinese Patients with Chronic Hepatitis B Virus Infection. <i>PLoS ONE</i> , 2011, 6, e28798.	1.1	56
98	TCGA whole-transcriptome sequencing data reveals significantly dysregulated genes and signaling pathways in hepatocellular carcinoma. <i>Frontiers of Medicine</i> , 2015, 9, 322-330.	1.5	56
99	Hepatic IFIT3 predicts interferon- α therapeutic response in patients of hepatocellular carcinoma. <i>Hepatology</i> , 2017, 66, 152-166.	3.6	56
100	HELLS Regulates Chromatin Remodeling and Epigenetic Silencing of Multiple Tumor Suppressor Genes in Human Hepatocellular Carcinoma. <i>Hepatology</i> , 2019, 69, 2013-2030.	3.6	56
101	Clinical outcome and virologic profiles of severe hepatitis B exacerbation due to YMDD mutations. <i>Journal of Hepatology</i> , 2003, 39, 850-855.	1.8	55
102	PIM1 regulates glycolysis and promotes tumor progression in hepatocellular carcinoma. <i>Oncotarget</i> , 2015, 6, 10880-10892.	0.8	55
103	Liver tumor-initiating cells as a therapeutic target for hepatocellular carcinoma. <i>Cancer Letters</i> , 2013, 338, 101-109.	3.2	52
104	Significance of HBV DNA Levels in Liver Histology of HBeAg and Anti-HBe Positive Patients with Chronic Hepatitis B. <i>American Journal of Gastroenterology</i> , 2004, 99, 2032-2037.	0.2	51
105	Cancer stemness in hepatocellular carcinoma: mechanisms and translational potential. <i>British Journal of Cancer</i> , 2020, 122, 1428-1440.	2.9	51
106	High-density allelotyping of chromosome 8p in hepatocellular carcinoma and clinicopathologic correlation. <i>Cancer</i> , 2002, 94, 3179-3185.	2.0	49
107	Virus-Clip: a fast and memory-efficient viral integration site detection tool at single-base resolution with annotation capability. <i>Oncotarget</i> , 2015, 6, 20959-20963.	0.8	49
108	Knock-down of hepatitis B virus X protein reduces the tumorigenicity of hepatocellular carcinoma cells. <i>Journal of Pathology</i> , 2006, 208, 372-380.	2.1	48

#	ARTICLE	IF	CITATIONS
109	Exosomes derived from V β 2-T cells control Epstein-Barr virus-associated tumors and induce T cell antitumor immunity. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	48
110	Over-expression of Id-1 induces cell proliferation in hepatocellular carcinoma through inactivation of p16INK4a/RB pathway. <i>Carcinogenesis</i> , 2003, 24, 1729-1736.	1.3	47
111	Cripto-1 contributes to stemness in hepatocellular carcinoma by stabilizing Dishevelled-3 and activating Wnt/ β 2-catenin pathway. <i>Cell Death and Differentiation</i> , 2018, 25, 1426-1441.	5.0	47
112	Galectin-1 promotes hepatocellular carcinoma and the combined therapeutic effect of OTX008 galectin-1 inhibitor and sorafenib in tumor cells. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 423.	3.5	47
113	miR-874-3p is down-regulated in hepatocellular carcinoma and negatively regulates PIN1 expression. <i>Oncotarget</i> , 2017, 8, 11343-11355.	0.8	47
114	Deleted in Liver Cancer 1 (DLC1) Utilizes a Novel Binding Site for Tensin2 PTB Domain Interaction and Is Required for Tumor-Suppressive Function. <i>PLoS ONE</i> , 2009, 4, e5572.	1.1	46
115	Suppression of ACADM-Mediated Fatty Acid Oxidation Promotes Hepatocellular Carcinoma via Aberrant CAV1/SREBP1 Signaling. <i>Cancer Research</i> , 2021, 81, 3679-3692.	0.4	45
116	EZH2-Mediated H3K27me3 Is Involved in Epigenetic Repression of Deleted in Liver Cancer 1 in Human Cancers. <i>PLoS ONE</i> , 2013, 8, e68226.	1.1	45
117	Liver Transplantation for Combined Hepatocellular Cholangiocarcinoma. <i>Asian Journal of Surgery</i> , 2007, 30, 143-146.	0.2	43
118	Variations in clinical presentations of the simple bone cyst: report of cases. <i>Journal of Oral and Maxillofacial Surgery</i> , 2003, 61, 1487-1491.	0.5	42
119	RhoE is frequently down-regulated in hepatocellular carcinoma (HCC) and suppresses HCC invasion through antagonizing the Rho/Rho-Kinase/Myosin phosphatase target pathway. <i>Hepatology</i> , 2013, 57, 152-161.	3.6	42
120	MicroRNA-142-3p and microRNA-142-5p are downregulated in hepatocellular carcinoma and exhibit synergistic effects on cell motility. <i>Frontiers of Medicine</i> , 2015, 9, 331-343.	1.5	42
121	RALYL increases hepatocellular carcinoma stemness by sustaining the mRNA stability of TGF- β 2. <i>Nature Communications</i> , 2021, 12, 1518.	5.8	42
122	Safety and outcome of hepatitis B core antibody-positive donors in right-lobe living donor liver transplantation. <i>Liver Transplantation</i> , 2003, 9, 827-832.	1.3	41
123	Solution structures, dynamics, and lipid-binding of the sterile β -motif domain of the deleted in liver cancer 2. <i>Proteins: Structure, Function and Bioinformatics</i> , 2007, 67, 1154-1166.	1.5	41
124	SERPINA5 inhibits tumor cell migration by modulating the fibronectin-integrin β 1 signaling pathway in hepatocellular carcinoma. <i>Molecular Oncology</i> , 2014, 8, 366-377.	2.1	41
125	Hepatitis B Virus-Telomerase Reverse Transcriptase Promoter Integration Harnesses Host ELF4, Resulting in Telomerase Reverse Transcriptase Gene Transcription in Hepatocellular Carcinoma. <i>Hepatology</i> , 2021, 73, 23-40.	3.6	41
126	Exogenous expression of p21WAF1/CIP1 exerts cell growth inhibition and enhances sensitivity to cisplatin in hepatoma cells. <i>Cancer Letters</i> , 2001, 172, 7-15.	3.2	40

#	ARTICLE	IF	CITATIONS
127	Chemopreventive Effect of PSP Through Targeting of Prostate Cancer Stem Cell-Like Population. PLoS ONE, 2011, 6, e19804.	1.1	40
128	Hepatitis B Virus-Associated Multistep Hepatocarcinogenesis: A Stepwise Increase in Allelic Alterations. Cancer Research, 2008, 68, 5988-5996.	0.4	39
129	Histone chaperone FACT complex mediates oxidative stress response to promote liver cancer progression. Gut, 2020, 69, 329-342.	6.1	39
130	Genetic and epigenetic inactivation of <i>E-cadherin</i> in human hepatocellular carcinoma cells. International Journal of Cancer, 2008, 123, 1043-1052.	2.3	38
131	Role and significance of focal adhesion proteins in hepatocellular carcinoma. Journal of Gastroenterology and Hepatology (Australia), 2009, 24, 520-530.	1.4	38
132	RhoGTPases and Rho-effectors in hepatocellular carcinoma metastasis: ROCK N' Rho move it. Liver International, 2010, 30, 642-656.	1.9	38
133	Hypoxia-induced macropinocytosis represents a metabolic route for liver cancer. Nature Communications, 2022, 13, 954.	5.8	38
134	A Randomized Controlled Study Evaluating the Safety and Efficacy of Deferiprone Treatment in Thalassemia Major Patients from Hong Kong. Hemoglobin, 2006, 30, 263-274.	0.4	37
135	Secretory Stanniocalcin 1 promotes metastasis of hepatocellular carcinoma through activation of JNK signaling pathway. Cancer Letters, 2017, 403, 330-338.	3.2	37
136	NRF2/SHH signaling cascade promotes tumor-initiating cell lineage and drug resistance in hepatocellular carcinoma. Cancer Letters, 2020, 476, 48-56.	3.2	37
137	Granulin-1 Epithelin Precursor Renders Hepatocellular Carcinoma Cells Resistant to Natural Killer Cytotoxicity. Cancer Immunology Research, 2014, 2, 1209-1219.	1.6	36
138	Novel pre-mRNA splicing of intronically integrated HBV generates oncogenic chimera in hepatocellular carcinoma. Journal of Hepatology, 2016, 64, 1256-1264.	1.8	36
139	High frequency of chimerism in transplanted livers. Hepatology, 2003, 38, 989-998.	3.6	36
140	Ephrin-A3/EphA2 axis regulates cellular metabolic plasticity to enhance cancer stemness in hypoxic hepatocellular carcinoma. Journal of Hepatology, 2022, 77, 383-396.	1.8	36
141	Meta-analysis of GWAS on two Chinese populations followed by replication identifies novel genetic variants on the X chromosome associated with systemic lupus erythematosus. Human Molecular Genetics, 2015, 24, 274-284.	1.4	35
142	Mechanisms through Which Hypoxia-Induced Caveolin-1 Drives Tumorigenesis and Metastasis in Hepatocellular Carcinoma. Cancer Research, 2016, 76, 7242-7253.	0.4	35
143	N-linked glycosylation is required for optimal proteolytic activation of membrane-bound transcription factor CREB-H. Journal of Cell Science, 2010, 123, 1438-1448.	1.2	34
144	Akt Phosphorylation of Deleted in Liver Cancer 1 Abrogates Its Suppression of Liver Cancer Tumorigenesis and Metastasis. Gastroenterology, 2010, 139, 1397-1407.e6.	0.6	34

#	ARTICLE	IF	CITATIONS
145	Tensin4 is up-regulated by EGF-induced ERK1/2 activity and promotes cell proliferation and migration in hepatocellular carcinoma. <i>Oncotarget</i> , 2015, 6, 20964-20976.	0.8	34
146	The relative contribution of CHK1 and CHK2 to Adriamycin-induced checkpoint. <i>Experimental Cell Research</i> , 2005, 304, 1-15.	1.2	33
147	The effect of wide resection margin in patients with intrahepatic cholangiocarcinoma. <i>Medicine (United States)</i> , 2016, 95, e4133.	0.4	33
148	Hepatitis serology predicts tumor and liver-disease characteristics but not prognosis after resection of hepatocellular carcinoma. <i>Journal of Gastrointestinal Surgery</i> , 2004, 8, 794-805.	0.9	32
149	Ketamine-Induced Cholangiopathy: A Case Report. <i>American Journal of Gastroenterology</i> , 2011, 106, 1004-1005.	0.2	32
150	PAK4 Phosphorylates p53 at Serine 215 to Promote Liver Cancer Metastasis. <i>Cancer Research</i> , 2016, 76, 5732-5742.	0.4	32
151	Patient plgR-enriched extracellular vesicles drive cancer stemness, tumorigenesis and metastasis in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2022, 76, 883-895.	1.8	32
152	Low Molecular Weight Heparin-Induced Liver Toxicity. <i>Journal of Clinical Pharmacology</i> , 2001, 41, 691-694.	1.0	31
153	Impact of Preoperative Fine-needle Aspiration Cytologic Examination on Clinical Outcome in Patients With Hepatocellular Carcinoma in a Tertiary Referral Center. <i>Archives of Surgery</i> , 2004, 139, 193.	2.3	31
154	Portal inflow and pressure changes in right liver living donor liver transplantation including the middle hepatic vein. <i>Liver Transplantation</i> , 2011, 17, 115-121.	1.3	31
155	Hepatitis transactivator protein X promotes extracellular matrix modification through HIF/LOX pathway in liver cancer. <i>Oncogenesis</i> , 2018, 7, 44.	2.1	31
156	Prognostic significance of pathological and biological factors in hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1998, 13, 666-670.	1.4	30
157	Gene delivery using a receptor-mediated gene transfer system targeted to hepatocellular carcinoma cells. <i>International Journal of Cancer</i> , 2001, 93, 393-400.	2.3	30
158	Rapamycin and CCI-779 inhibit the mammalian target of rapamycin signalling in hepatocellular carcinoma. <i>Liver International</i> , 2010, 30, 65-75.	1.9	30
159	Role of cadherin-17 in oncogenesis and potential therapeutic implications in hepatocellular carcinoma. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2010, 1806, 138-145.	3.3	30
160	The potential contributions of a Y-located protooncogene and its X homologue in sexual dimorphisms in hepatocellular carcinoma. <i>Human Pathology</i> , 2014, 45, 1847-1858.	1.1	30
161	Nuclear Met promotes hepatocellular carcinoma tumorigenesis and metastasis by upregulation of TAK1 and activation of NF- κ B pathway. <i>Cancer Letters</i> , 2017, 411, 150-161.	3.2	30
162	RSK2-inactivating mutations potentiate MAPK signaling and support cholesterol metabolism in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2021, 74, 360-371.	1.8	30

#	ARTICLE	IF	CITATIONS
163	Genome-wide CRISPR-Cas9 knockout library screening identified PTPMT1 in cardiolipin synthesis is crucial to survival in hypoxia in liver cancer. <i>Cell Reports</i> , 2021, 34, 108676.	2.9	30
164	RhoE/ROCK2 regulates chemoresistance through NF- κ B/IL-6/ STAT3 signaling in hepatocellular carcinoma. <i>Oncotarget</i> , 0, 7, 41445-41459.	0.8	30
165	C-terminal truncated hepatitis B virus X protein regulates tumorigenicity, self-renewal and drug resistance via STAT3/Nanog signaling pathway. <i>Oncotarget</i> , 2017, 8, 23507-23516.	0.8	29
166	Fibrosing cholestatic hepatitis secondary to precore/core promoter hepatitis B variant with lamivudine resistance: Successful retransplantation with combination adefovir dipivoxil and hepatitis B immunoglobulin. <i>Liver Transplantation</i> , 2004, 10, 557-563.	1.3	28
167	Integrin-Linked Kinase Overexpression and Its Oncogenic Role in Promoting Tumorigenicity of Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2011, 6, e16984.	1.1	28
168	PKA-induced dimerization of the RhoGAP DLC1 promotes its inhibition of tumorigenesis and metastasis. <i>Nature Communications</i> , 2013, 4, 1618.	5.8	28
169	Antibody against Granulin α Epithelin Precursor Sensitizes Hepatocellular Carcinoma to Chemotherapeutic Agents. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 3001-3012.	1.9	28
170	Genome-wide search followed by replication reveals genetic interaction of <i>CD80</i> and <i>ALOX5AP</i> associated with systemic lupus erythematosus in Asian populations. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 891-898.	0.5	28
171	Deleted in Liver Cancer 2 (DLC2) Was Dispensable for Development and Its Deficiency Did Not Aggravate Hepatocarcinogenesis. <i>PLoS ONE</i> , 2009, 4, e6566.	1.1	28
172	Mitochondrial targeting of growth suppressor protein DLC2 through the START domain. <i>FEBS Letters</i> , 2006, 580, 191-198.	1.3	25
173	CDK5RAP3 Is a Novel Repressor of p14ARF in Hepatocellular Carcinoma Cells. <i>PLoS ONE</i> , 2012, 7, e42210.	1.1	25
174	Post-transplant lymphoproliferative disorders in liver transplant recipients: a clinicopathological study. <i>Journal of Clinical Pathology</i> , 2013, 66, 392-398.	1.0	25
175	Tensin2 variant 3 is associated with aggressive tumor behavior in human hepatocellular carcinoma. <i>Hepatology</i> , 2006, 44, 881-890.	3.6	24
176	<i>HAI-2</i> is epigenetically downregulated in human hepatocellular carcinoma, and its Kunitz domain type 1 is critical for anti-invasive functions. <i>International Journal of Cancer</i> , 2009, 124, 1811-1819.	2.3	24
177	Transcriptional Repressive H3K9 and H3K27 Methylations Contribute to DNMT1-Mediated DNA Methylation Recovery. <i>PLoS ONE</i> , 2011, 6, e16702.	1.1	24
178	Osteomyelitis with proliferative periostitis: an unusual case. <i>Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontics</i> , 2006, 102, e14-e19.	1.6	23
179	Deleted in liver cancer 2 suppresses cell growth via the regulation of the Raf-1-ERK1/2-p70S6K signalling pathway. <i>Liver International</i> , 2010, 30, 1315-1323.	1.9	23
180	Hepatocellular tumors: Immunohistochemical analyses for classification and prognostication. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association</i> , Beijing Institute for Cancer Research, 2011, 23, 245-253.	0.7	23

#	ARTICLE	IF	CITATIONS
181	Requirement of CRTC1 coactivator for hepatitis B virus transcription. <i>Nucleic Acids Research</i> , 2014, 42, 12455-12468.	6.5	23
182	The interplay of UBE2T and Mule in regulating Wnt/ β -catenin activation to promote hepatocellular carcinoma progression. <i>Cell Death and Disease</i> , 2021, 12, 148.	2.7	23
183	Caspase-3-Induced Activation of SREBP2 Drives Drug Resistance via Promotion of Cholesterol Biosynthesis in Hepatocellular Carcinoma. <i>Cancer Research</i> , 2022, 82, 3102-3115.	0.4	22
184	Identification of Carboxypeptidase of Glutamate Like-B as a Candidate Suppressor in Cell Growth and Metastasis in Human Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2006, 12, 6617-6625.	3.2	21
185	Role of a Novel Splice Variant of Mitotic Arrest Deficient 1 (MAD1), MAD1 β , in Mitotic Checkpoint Control in Liver Cancer. <i>Cancer Research</i> , 2008, 68, 9194-9201.	0.4	21
186	Gene expression profiling by cDNA array in human hepatoma cell line in response to cisplatin treatment. <i>Life Sciences</i> , 2002, 70, 1677-1690.	2.0	20
187	Epigenetic dysregulation in hepatocellular carcinoma: focus on polycomb group proteins. <i>Frontiers of Medicine</i> , 2013, 7, 231-241.	1.5	20
188	Antioxidant supplements promote tumor formation and growth and confer drug resistance in hepatocellular carcinoma by reducing intracellular ROS and induction of TMBIM1. <i>Cell and Bioscience</i> , 2021, 11, 217.	2.1	20
189	C-terminal truncated HBx protein activates caveolin-1/LRP6/ β -catenin/FRMD5 axis in promoting hepatocarcinogenesis. <i>Cancer Letters</i> , 2019, 444, 60-69.	3.2	19
190	APOBEC3B promotes hepatocarcinogenesis and metastasis through novel deaminase-independent activity. <i>Molecular Carcinogenesis</i> , 2019, 58, 643-653.	1.3	19
191	Bromodomain-containing protein BRPF1 is a therapeutic target for liver cancer. <i>Communications Biology</i> , 2021, 4, 888.	2.0	18
192	Deleted in liver cancer 1 isoforms are distinctly expressed in human tissues, functionally different and under differential transcriptional regulation in hepatocellular carcinoma. <i>Liver International</i> , 2010, 30, 139-148.	1.9	17
193	Polysaccharopeptide enhanced the anti-cancer effect of gamma-tocotrienol through activation of AMPK. <i>BMC Complementary and Alternative Medicine</i> , 2014, 14, 303.	3.7	16
194	Asymmetric localization of DLC1 defines avian trunk neural crest polarity for directional delamination and migration. <i>Nature Communications</i> , 2017, 8, 1185.	5.8	16
195	Inhibition of CMTM4 Sensitizes Cholangiocarcinoma and Hepatocellular Carcinoma to T Cell-Mediated Antitumor Immunity Through PD-L1. <i>Hepatology Communications</i> , 2022, 6, 178-193.	2.0	16
196	Polo-like kinase 4 inhibitor CFI400945 suppresses liver cancer through cell cycle perturbation and eliciting antitumor immunity. <i>Hepatology</i> , 2023, 77, 729-744.	3.6	16
197	Cholangiocarcinoma in liver cirrhosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2003, 18, 337-341.	1.4	14
198	Nuclear-Targeted Deleted in Liver Cancer 1 (DLC1) Is Less Efficient in Exerting Its Tumor Suppressive Activity Both In Vitro and In Vivo. <i>PLoS ONE</i> , 2011, 6, e25547.	1.1	14

#	ARTICLE	IF	CITATIONS
199	Solution Structure of the Phosphotyrosine Binding (PTB) Domain of Human Tensin2 Protein in Complex with Deleted in Liver Cancer 1 (DLC1) Peptide Reveals a Novel Peptide Binding Mode. <i>Journal of Biological Chemistry</i> , 2012, 287, 26104-26114.	1.6	14
200	Deregulated GATA6 modulates stem cell-like properties and metabolic phenotype in hepatocellular carcinoma. <i>International Journal of Cancer</i> , 2019, 145, 1860-1873.	2.3	14
201	The centrosomal protein tax1 binding protein 2 is a novel tumor suppressor in hepatocellular carcinoma regulated by cyclin-dependent kinase 2. <i>Hepatology</i> , 2012, 56, 1770-1781.	3.6	13
202	Adaptive and Constitutive Activations of Malic Enzymes Confer Liver Cancer Multilayered Protection Against Reactive Oxygen Species. <i>Hepatology</i> , 2021, 74, 776-796.	3.6	13
203	Intraoperative Iatrogenic Rupture of Hepatocellular Carcinoma. <i>World Journal of Surgery</i> , 2002, 26, 348-352.	0.8	12
204	Allelic alterations in nontumorous liver tissues and corresponding hepatocellular carcinomas from chinese patients. <i>Human Pathology</i> , 2003, 34, 699-705.	1.1	12
205	Nuclear DLC1 exerts oncogenic function through association with FOXK1 for cooperative activation of MMP9 expression in melanoma. <i>Oncogene</i> , 2020, 39, 4061-4076.	2.6	12
206	Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. , 2000, 89, 500.		12
207	Phosphorylation of Nucleophosmin at Threonine 234/237 is associated with HCC metastasis. <i>Oncotarget</i> , 2015, 6, 43483-43495.	0.8	12
208	Oval Cells Contribute to Fibrogenesis of Marginal Liver Grafts under Stepwise Regulation of Aldose Reductase and Notch Signaling. <i>Theranostics</i> , 2017, 7, 4879-4893.	4.6	11
209	Joining the dots for better liver cancer treatment. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020, 17, 74-75.	8.2	10
210	Reversal of Protein-Losing Enteropathy by Liver Transplantation. <i>Journal of Clinical Gastroenterology</i> , 2003, 36, 86-87.	1.1	10
211	Anti-tumour effects of PIM kinase inhibition on progression and chemoresistance of hepatocellular carcinoma. <i>Journal of Pathology</i> , 2020, 252, 65-76.	2.1	9
212	Significance of serum DKK1 as a diagnostic biomarker in hepatocellular carcinoma. <i>Future Oncology</i> , 2012, 8, 1525-1528.	1.1	8
213	Proteomic profiling in liver cancer: another new page. <i>Translational Gastroenterology and Hepatology</i> , 2019, 4, 47-47.	1.5	8
214	Lymphoepithelioma-like neoplasm of the biliary tract with "probable low malignant potential"™. <i>Histopathology</i> , 2022, 80, 720-728.	1.6	8
215	Cancer stem cells: advances in biology and clinical translation—a Keystone Symposia report. <i>Annals of the New York Academy of Sciences</i> , 2021, 1506, 142-163.	1.8	8
216	Liquid Biopsy Using Cell-Free or Circulating Tumor DNA in the Management of Hepatocellular Carcinoma. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2022, 13, 1611-1624.	2.3	8

#	ARTICLE	IF	CITATIONS
217	Meta-analysis of two Chinese populations identifies an autoimmune disease risk allele in 22q11.21 as associated with systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2015, 17, 67.	1.6	6
218	Knowledge-based analyses reveal new candidate genes associated with risk of hepatitis B virus related hepatocellular carcinoma. <i>BMC Cancer</i> , 2020, 20, 403.	1.1	6
219	Association of MAD2 expression with mitotic checkpoint competence in hepatoma cells. , 2004, 11, 920.		6
220	Dishevelled-3 phosphorylation is governed by HIPK2/PP1/ITCH axis and the non-phosphorylated form promotes cancer stemness via LGR5 in hepatocellular carcinoma. <i>Oncotarget</i> , 2017, 8, 39430-39442.	0.8	6
221	Histone chaperone FACT complex coordinates with HIF to mediate an expeditious transcription program to adapt to poorly oxygenated cancers. <i>Cell Reports</i> , 2022, 38, 110304.	2.9	6
222	Single-Cell Transcriptomics of Liver Cancer: Hype or Insights?. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2022, 14, 513-525.	2.3	6
223	Protein-Losing Enteropathy Due to T-Cell Large Granular Lymphocyte Leukemia. <i>Journal of Clinical Oncology</i> , 2009, 27, 2097-2098.	0.8	5
224	Proline-rich acidic protein 1 (PRAP1) is a novel interacting partner of MAD1 and has a suppressive role in mitotic checkpoint signalling in hepatocellular carcinoma. <i>Journal of Pathology</i> , 2014, 233, 51-60.	2.1	5
225	Variation of stemness markers expression in tumor nodules from synchronous multi-focal hepatocellular carcinoma – an immunohistochemical study. <i>Diagnostic Pathology</i> , 2017, 12, 56.	0.9	5
226	Centrosomal protein TAX1BP2 inhibits centrosome-microtubules aberrations induced by hepatitis B virus X oncoprotein. <i>Cancer Letters</i> , 2020, 492, 147-161.	3.2	5
227	Dysregulation of RalA signaling through dual regulatory mechanisms exerts its oncogenic functions in hepatocellular carcinoma. <i>Hepatology</i> , 2022, 76, 48-65.	3.6	5
228	Immunoglobulin G4-related sclerosing disease involving the mandible. <i>Hong Kong Medical Journal</i> , 2017, 23, 534-536.	0.1	4
229	Investigation of Functional Synergism of CENPF and FOXM1 Identifies POLD1 as Downstream Target in Hepatocellular Carcinoma. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	4
230	Clinicopathologic and Prognostic Significance of the Histologic Activity of Noncancerous Liver Tissue in Hepatitis B Virus-Associated Hepatocellular Carcinoma. <i>American Journal of Clinical Pathology</i> , 2002, 117, 411-418.	0.4	3
231	uGPA: unified Gene Pathway Analyzer package for high-throughput genome-wide screening data provides mechanistic overview on human diseases. <i>Clinica Chimica Acta</i> , 2015, 441, 105-108.	0.5	3
232	Hormonal control of the metabolic machinery of hepatocellular carcinoma. <i>Hepatobiliary Surgery and Nutrition</i> , 2016, 5, 195-197.	0.7	3
233	Imaging of follicular dendritic cell tumours of the liver. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1998, 13, 1146-1151.	1.4	2
234	Expression of hepatic progenitor cell markers in acute cellular rejection of liver allografts—An immunohistochemical study. <i>Clinical Transplantation</i> , 2018, 32, e13203.	0.8	2

#	ARTICLE	IF	CITATIONS
235	Liver allograft biopsies with histological cholestasis: a clinicopathological study of 254 cases from a single centre. <i>Journal of Clinical Pathology</i> , 2018, 71, 72-78.	1.0	2
236	Molecular and cellular pathology of hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 1998, 13, S299-S303.	1.4	1
237	Gene expression profiles of different stages of hepatocarcinogenesis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008, 23, 1-3.	1.4	0
238	Reply to: "Deregulation of microRNAs expression occurs in stages of multistep hepatocarcinogenesis: Why is it different?" <i>Journal of Hepatology</i> , 2012, 56, 1426-1427.	1.8	0
239	Histological Mimicker of Hepatocellular Carcinoma in the Liver. , 2014, 19, 305-308.		0
240	Genomics of Hepatocellular Carcinoma. , 2012, , 45-78.		0
241	Epigenetic Regulation of EZH2 and Its Targeted MicroRNAs. , 2013, , 33-61.		0
242	Do statins reduce the risk of hepatocellular carcinoma in patients with chronic hepatitis B?. <i>Hepatobiliary Surgery and Nutrition</i> , 2013, 2, 34-6.	0.7	0
243	Single cell analysis informing therapy response in hepatocellular carcinoma and intrahepatic cholangiocarcinoma. <i>Hepatobiliary Surgery and Nutrition</i> , 2021, 11, 0-0.	0.7	0
244	Reply to: "EFNA3 is a prognostic biomarker for the overall survival of patients with hepatocellular carcinoma". <i>Journal of Hepatology</i> , 2022, , .	1.8	0